Ann: Deferral of Intergen vendor payments and Appendix 3B, page-2

Positives from this ann that I can see

1. Will improve short term (H2 FY2016) balance sheets, and should result in higher EBITDA/NPAT
2. Director confidence in the company by being happy to accept 30c shares over cash
3. Works out well for the Intergen directors by giving them cheap shares which they are unable to buy on market (due to director sharepurchase restrictions).

Let's see if the market also agrees that this is positive.